InVivoMAb Anti-Bordetella pertussis cyaA/Cyclolysin Antibody (Iv0145)

Description: InVivoMAb Anti-Bordetella pertussis cyaA/Cyclolysin Antibody (Iv0145) [Iv0145] (RA11829) is a human monoclonal antibody detecting Bifunctional hemolysin/adenylate cyclase in ELISA.
Host species: Human
Isotype: IgG1
Species reactivity: Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251)
Form: Liquid
Storage buffer: 0.01M PBS, pH 7.4.
Concentration: 1 mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: ELISA
Target: Bifunctional hemolysin/adenylate cyclase, AC-HLY, ACT, Cyclolysin, Calmodulin-sensitive adenylate cyclase, 4.6.1.1, ATP pyrophosphate-lyase, Adenylyl cyclase, Hemolysin, cya, cyaA, BP0760
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: Please contact with the lab for this information.
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names:
Background: Bifunctional hemolysin/adenylate cyclase (cyaA/Cyclolysin) is a ~177 kDa protein. Bifunctional adenylate cyclase toxin-hemolysin that plays a crucial role in host colonization. It causes whooping cough by acting on mammalian cells by elevating cAMP-concentration and thus disrupts normal cell function.
References:
1. Glaser, P. et al. (1991) The EMBO journal 10, 1683-8. PMID: 2050107
2. Glaser, P. et al. (1989) The EMBO journal 8, 967-72. PMID: 2542030
Note: For research use only. Not suitable for clinical or therapeutic use.